Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide.Continue reading
Author Archive: Roxan Olivas
C-Path Taps Veteran Health Technology Leader to Drive Data and AI Strategy as Chief Data and Technology Officer
TUCSON, Ariz., March 24, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Christopher Lunt as its Chief Data and Technology Officer. Lunt is a technology executive with more than 25 years of experience building large-scale data and analytics platforms across the federal government, Silicon Valley, and the healthcare sector. Continue reading
New Study on Early Parkinson’s Disease Progression Highlights Vital Role of Patient Focused Drug Development and Real-World Impacts
TUCSON, Ariz., March 10, 2026– Critical Path Institute® (C-Path) applauds the publication of a new study in the Journal of Neurology that offers critical longitudinal insights into how symptoms and functional impacts evolve for individuals with early Parkinson’s disease (PD).Continue reading
C-Path’s Translational Therapeutics Accelerator Announces 2026 Request for Proposals from Academic Investigators
Included is a dedicated polycystic kidney disease track alongside investments in brain health, pediatrics, and rare diseases.Continue reading
C-Path Consortium Adds Gene Editing and Advanced Imaging Leaders to Accelerate Alpha-1 Research
Beam Therapeutics and the Open Source Imaging Consortium join C-Path’s CPA-1 program, bringing gene editing innovation and global lung imaging data resources to advance new therapies for alpha-1 antitrypsin deficiency.Continue reading
C-Path Announces New Name and Strategic Direction for its PRO Consortium
Newly renamed Patient-Centered Evidence Consortium expands focus to advance the science and impact of patient-centered evidence in drug development.Continue reading
C-Path’s International Neonatal Consortium Launches Groundbreaking Neonatal Lab Values GUI Tool to Standardize Reference Ranges in Neonatal Trials
TUCSON, Ariz., November 2025 — Critical Path Institute’s® (C-Path) International Neonatal Consortium (INC) today announced the public launch of its Neonatal Laboratory Values Graphical User Interface (Neo-LV) Tool, a first-of-its-kind platform designed to harmonize and standardize laboratory reference ranges in neonatal research and clinical trials.Continue reading
FDA Qualifies C-Path Biomarker GLDH to Detect Liver Injury in Clinical Trials
C-Path’s Predictive Safety Testing Consortium led effort to qualify liver-specific biomarker to improve safety monitoring in those with muscle disease.Continue reading
C-Path’s Disease Modeling Coalition Begins Global Pediatric IBD Work from European Hub
AMSTERDAM, October 16, 2025 — Critical Path Institute® (C-Path) today announced the official launch of the Critical Path Disease Modeling Coalition (CP-DMC) on pediatric inflammatory bowel disease (pIBD).Continue reading
Critical Path Institute to be Honored with Reagan-Udall Foundation Innovation Award
Award honors regulatory science advances with measurable public health impact; ceremony December 9, 2025, Willard InterContinental, Washington, D.C.Continue reading